Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SYH2053 Injection

Phase 3

CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Heterozygous Familial Hypercholesterolemia (hefh)Recruiting

Heterozygous Familial Hypercholesterolemia (hefh)Phase 3

Recruiting

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Heterozygous Familial Hypercholesterolemia (hefh)

NCT07465263

Clinical

Trials by Indication[1]

Heterozygous Familial Hypercholesterolemia (HeFH)1 trial

A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Clinical Trial

Recruiting·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 3·NCT07465263·135 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SYH2053 Injection. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for SYH2053 Injection. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Related News